Co-Authors
This is a "connection" page, showing publications co-authored by Marc Lipsitch and Nir Eyal.
Connection Strength
5.519
-
How to Test Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines Ethically Even After One Is Available. Clin Infect Dis. 2021 12 16; 73(12):2332-2334.
Score: 0.985
-
Testing SARS-CoV-2 vaccine efficacy through deliberate natural viral exposure. Clin Microbiol Infect. 2021 Mar; 27(3):372-377.
Score: 0.923
-
Opinion: It's ethical to test promising coronavirus vaccines against less-promising ones. Proc Natl Acad Sci U S A. 2020 08 11; 117(32):18898-18901.
Score: 0.894
-
Improving vaccine trials in infectious disease emergencies. Science. 2017 07 14; 357(6347):153-156.
Score: 0.725
-
Vaccine testing for emerging infections: the case for individual randomisation. J Med Ethics. 2017 09; 43(9):625-631.
Score: 0.712
-
Reply to Hasford and to Spinola et al. J Infect Dis. 2020 10 01; 222(9):1574-1575.
Score: 0.226
-
Response to Dawson et al. J Infect Dis. 2020 07 06; 222(3):516-517.
Score: 0.223
-
Response to Cioffi. J Infect Dis. 2020 06 16; 222(1):169-170.
Score: 0.222
-
Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure. J Infect Dis. 2020 05 11; 221(11):1752-1756.
Score: 0.220
-
Choices in vaccine trial design in epidemics of emerging infections. PLoS Med. 2018 08; 15(8):e1002632.
Score: 0.195
-
Opinion: Risk to study nonparticipants: A procedural approach. Proc Natl Acad Sci U S A. 2018 08 07; 115(32):8051-8053.
Score: 0.195